Oncology-focused biotech company Exelixis Inc (NASDAQ:EXEL) and US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, on Monday announced a clinical development collaboration to evaluate zanzalintinib, Exelixis' investigational tyrosine kinase inhibitor, in combination with KEYTRUDA (pembrolizumab) for head and neck cancer and with WELIREG (belzutifan) for renal cell carcinoma.
Under the terms of the collaboration, Merck will supply KEYTRUDA for the ongoing, Exelixis-sponsored STELLAR-305 trial in head and neck squamous cell carcinoma and will sponsor a phase 1/2 trial and two phase 3 pivotal trials in renal cell carcinoma.
Merck will fund one of these phase 3 studies, and Exelixis will co-fund the phase 1/2 trial and the other phase 3 study, as well as supply zanzalintinib and cabozantinib. Exelixis maintains all global commercial and marketing rights to zanzalintinib.
GSK PLC announces acceptance of NDA for gepotidacin by US FDA
Anixa Biosciences administers second dose of CAR-T therapy to individual patient
RevOpsis Therapeutics receives SBIR grant of over USD1.8m
AtomVie Global Radiopharma partners with Radiopharm Ventures
Lipella granted patent for innovative drug delivery technology
Adocia patents stable hormone combinations for obesity and diabetes
Accord BioPharma's IMULDOSA receives US FDA approval to treat chronic inflammatory conditions
RedHill Biopharma's opaganib selected for Ebola treatment development by BARDA
Quest Diagnostics acquires OhioHealth lab assets
Exelixis and Merck collaborate on clinical development of zanzalintinib
BD launches automated reagent kit to streamline single-cell discovery studies
Transgene's Phase II trial of TG4001 falls short of primary objective
GSK reports positive Phase III results for depemokimab in chronic rhinosinusitis with nasal polyps
SkylineDx reveals new data from the MERLIN_001 prospective US multi-centre trial